SQZ Biotechnologies Current Ratio 2020-2021 | SQZ

SQZ Biotechnologies current ratio from 2020 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
SQZ Biotechnologies Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-09-30 $0.17B $0.04B 4.25
2021-06-30 $0.19B $0.04B 4.32
2021-03-31 $0.21B $0.04B 4.98
2020-12-31 $0.18B $0.05B 3.91
2020-09-30 $0.12B $0.05B 2.35
2020-06-30 $0.00B 0.00
2020-03-31 $0.00B 0.00
2019-12-31 $0.00B 0.00
2019-09-30 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.319B $0.021B
SQZ Biotechnologies Company is a clinical-stage biotechnology company. It develops transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. The company's prime product candidate consist SQZ-PBMC-HPV which is in clinical stage. SQZ Biotechnologies Company is based In Watertown, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.010B 7.90
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.357B 20.93
Biohaven Pharmaceutical Holding (BHVN) United States $6.783B 0.00
Arcus Biosciences (RCUS) United States $3.105B 0.00
Emergent Biosolutions (EBS) United States $2.254B 8.10
ADC Therapeutics SA (ADCT) Switzerland $1.478B 0.00
Myovant Sciences (MYOV) United Kingdom $1.368B 0.00
Zymeworks (ZYME) Canada $0.861B 0.00
Ambrx Biopharma (AMAM) United States $0.337B 0.00
Enzo Biochem (ENZ) United States $0.162B 15.90